U.S. FDA says carcinogen not found in alternatives of Zantac and its generics

US

FILE PHOTO: A bottle of Zantac heartburn drug is seen in this picture illustration taken October 1, 2019. REUTERS/Brendan McDermid/Illustration/File Photo

(Reuters) – The U.S. Food and Drug Administration said on Wednesday that alternatives to popular heartburn drug Zantac and its generic versions, known chemically as ranitidine, have not been found to contain the probable cancer-causing impurity that ranitidine has been linked to. (bit.ly/2oYJ1Vz)

U.S. retailers Walmart Inc, CVS Health Corp Walgreens Boots Alliance Inc and Rite Aid Corp have all removed Zantac off their shelves after some drugs containing its key ingredient ranitidine were found to have traces of the impurity, N-nitrosodimethylamine (NDMA).

Early tests of alternatives to over-the-counter ranitidine, such as Pepcid, Tagamet, Nexium, Prevacid and Prilosec show no NDMA, the agency said.

The FDA said earlier this month it found unacceptable levels of NDMA in drugs containing ranitidine. The regulator asked ranitidine makers to conduct their own testing to assess levels of the impurity and to send samples of their products for testing by the agency.

French drugmaker Sanofi SA last week said it would recall Zantac in the United States and Canada.

NDMA had previously been found in some blood pressure medicines from a class of drugs known as angiotensin II receptor blockers, or ARBs. The potentially cancer-causing impurities are believed to have been introduced by recent changes in the manufacturing process for the drugs.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber

Products You May Like

Articles You May Like

Missing radioactive capsule found in Australia
Most schools in England affected by strikes
UK to see shorter recession, says Bank of England
Energy firms asked to suspend prepayment meter installs
Man admits treason charge over Queen crossbow threat

Leave a Reply

Your email address will not be published. Required fields are marked *